These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. New antibiotics for paediatric use: a review of a decade of regulatory trials submitted to the European Medicines Agency from 2000--why aren't we doing better? Garazzino S; Lutsar I; Bertaina C; Tovo PA; Sharland M Int J Antimicrob Agents; 2013 Aug; 42(2):99-118. PubMed ID: 23810180 [TBL] [Abstract][Full Text] [Related]
25. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products. Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425 [TBL] [Abstract][Full Text] [Related]
28. New perspectives on the development of antiobesity drugs. Costantino L; Barlocco D Future Med Chem; 2015; 7(3):315-36. PubMed ID: 25826362 [TBL] [Abstract][Full Text] [Related]
29. Addressing insurance-related barriers to novel antiobesity medications: Lessons to be learned from bariatric surgery. Gasoyan H; Sarwer DB Obesity (Silver Spring); 2022 Dec; 30(12):2338-2339. PubMed ID: 36190393 [TBL] [Abstract][Full Text] [Related]
30. Natural compounds as obesity pharmacotherapies. Zhao XY; Wang JQ; Neely GG; Shi YC; Wang QP Phytother Res; 2024 Feb; 38(2):797-838. PubMed ID: 38083970 [TBL] [Abstract][Full Text] [Related]
32. The obesity pipeline: current strategies in the development of anti-obesity drugs. Cooke D; Bloom S Nat Rev Drug Discov; 2006 Nov; 5(11):919-31. PubMed ID: 17080028 [TBL] [Abstract][Full Text] [Related]
34. Why do we need drugs to treat the patient with obesity? Bray GA Obesity (Silver Spring); 2013 May; 21(5):893-9. PubMed ID: 23520198 [TBL] [Abstract][Full Text] [Related]
35. Should the Same Safety Scrutiny of Antiobesity Medications be Applied to Other Chronic Usage Drugs? Halpern B; Mancini MC Obesity (Silver Spring); 2020 Jul; 28(7):1171-1172. PubMed ID: 32374528 [TBL] [Abstract][Full Text] [Related]
36. National trends in antiobesity medication use. Stafford RS; Radley DC Arch Intern Med; 2003 May; 163(9):1046-50. PubMed ID: 12742801 [TBL] [Abstract][Full Text] [Related]
37. Aversion to Off-label Prescribing in Clinical Pediatric Weight Management: The Quintessential Double Standard. San Giovanni CB; Sweeney B; Skelton JA; Kelsey MM; Kelly AS J Clin Endocrinol Metab; 2021 Jun; 106(7):2103-2113. PubMed ID: 33901290 [TBL] [Abstract][Full Text] [Related]
38. New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier? Kennett GA; Clifton PG Pharmacol Biochem Behav; 2010 Nov; 97(1):63-83. PubMed ID: 20688100 [TBL] [Abstract][Full Text] [Related]
39. [Weight reduction. Antiobesity drug treatment in type-2 diabetics]. Verspohl EJ Pharm Unserer Zeit; 2002; 31(3):300-7. PubMed ID: 12071127 [No Abstract] [Full Text] [Related]
40. New molecular targets in the pathophysiology of obesity and available treatment options under investigation. Valsamakis G; Lois K; Kumar S; Mastorakos G Clin Obes; 2014 Aug; 4(4):209-19. PubMed ID: 25826792 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]